ReviewInflammation2025
The Kynurenine Pathway in Psoriasis: Mechanisms and Therapeutic Opportunities.
Review in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tryptophan Metabolism at the Crossroads of Immunity, Barrier Function, and the Microbiome in Atopic Dermatitis.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory disease driven by genetic and environmental factors, with pathogenesis closely linked to metabolic reprogramming and immune microenvironment dysregulation. The kynurenine pathway (KP), as the principal route of tryptophan catabolism, plays a pivotal role in regulating immune tolerance, oxidative stress, and neuroinflammation, thereby serving as a "metabolic bridge" that links cutaneous lesions to systemic comorbidities in psoriasis. This review systematically examines the pathological mechanisms of KP in psoriasis. Imbalances in the activities of indoleamine 2,3-dioxygenase (IDO) and kynureninase (KYNU) in patients with psoriasis lead to a pro-inflammatory shift in KP. Moreover, downstream KP metabolites mediate oxidative damage, endothelial dysfunction, and depletion of serotonin, which are closely associated with the increased risk of cardiovascular disease and depressive disorders commonly observed in psoriasis. Although therapeutic strategies targeting the KP, such as IDO overexpression and KYNU inhibition, have demonstrated promising potential, the complexity of the metabolic network and tissue-specific effects limit the clinical application of single-target therapies. Future studies should integrate multi-omics data to elucidate the dynamic regulatory network of the KP, develop multi-targeted modulators, and explore new paradigms for coordinated management of cutaneous and systemic comorbidities, thereby providing a solid theoretical foundation for precision treatment of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.